Biomarker signatures for progressive idiopathic pulmonary fibrosis

Britt Clynick, Tamera J. Corte, Helen E. Jo, Iain Stewart, Ian N. Glaspole, Christopher Grainge, Toby M. Maher, Vidya Navaratnam, Richard Hubbard, Peter M.A. Hopkins, Paul N. Reynolds, Sally Chapman, Christopher Zappala, Gregory J. Keir, Wendy A. Cooper, Annabelle M. Mahar, Samantha Ellis, Nicole S. Goh, Emma De Jong, Lilian ChaDino B.A. Tan, Lucy Leigh, Christopher Oldmeadow, E. Haydn Walters, R. Gisli Jenkins, Yuben Moodley

Research output: Contribution to journalArticlepeer-review

31 Citations (Scopus)


BACKGROUND: Idiopathic pulmonary fibrosis (IPF) is a progressive lung disease in which circulatory biomarkers have the potential for guiding management in clinical practice. We assessed the prognostic role of serum biomarkers in three independent IPF cohorts: Australian Idiopathic Pulmonary Fibrosis Registry (AIPFR), Trent Lung Fibrosis (TLF) and Prospective Observation of Fibrosis in the Lung Clinical Endpoints (PROFILE). METHODS: In the AIPFR cohort, candidate proteins were assessed by ELISA as well as in an unbiased proteomic approach. LASSO (least absolute shrinkage and selection operator) regression was used to restrict the selection of markers that best accounted for the progressor phenotype at 1 year in the AIPFR cohort, and subsequently prospectively selected for replication in the validation TLF cohort and assessed retrospectively in the PROFILE cohort. Four significantly replicating biomarkers were aggregated into a progression index model based on tertiles of circulating concentrations. RESULTS: 189 participants were included in the AIPFR cohort, 205 participants from the TLF cohort and 122 participants from the PROFILE cohort. Differential biomarker expression was observed by ELISA and replicated for osteopontin, matrix metallopeptidase-7, intercellular adhesion molecule-1 and periostin for those with a progressor phenotype at 1 year. Proteomic data did not replicate. The progression index in the AIPFR, TLF and PROFILE cohorts predicted risk of progression, mortality and progression-free survival. A statistical model incorporating the progression index demonstrated the capacity to distinguish disease progression at 12 months, which was increased beyond the clinical GAP (gender, age and physiology) score model alone in all cohorts, and significantly so within the incidence-based TLF and PROFILE cohorts. CONCLUSION: A panel of circulatory biomarkers can provide potentially valuable clinical assistance in the prognosis of IPF patients.

Original languageEnglish
Article number2101181
Number of pages12
JournalThe European Respiratory Journal
Issue number3
Publication statusPublished - 1 Mar 2022


Dive into the research topics of 'Biomarker signatures for progressive idiopathic pulmonary fibrosis'. Together they form a unique fingerprint.

Cite this